RESUMO
BACKGROUND: A new hyaluronic acid (HA) formulation was developed based on high molecular weight (MW) compounds used on the surface of the skin while using peptides to stimulate the high MW HA production by fibroblasts and keratinocytes from within the skin layers. Detailed science has been submitted to this journal in a previous publication. This multicenter study aims to validate the science by demonstrating the safety and efficacy of the product in the clinical realm. OBJECTIVES: This study evaluated the efficacy and safety of a topical HA serum in facial skin. METHODS: An open-label clinical study was undertaken over 4 months from November 2021 to March 2022. Participants applied the topical serum twice daily and were provided a gentle cleanser and an SPF 30+ to use in the morning. Follow-up visits were conducted at weeks 2, 4, and 8. At every visit, participants were measured for hydration post 15 minutes of cleansing the skin and post 15 minutes of product application for cumulative skin hydration sensor measurements. Additional procedures included participant assessments and satisfaction, investigator assessments, biopsies, and photography. RESULTS: At each follow-up visit, there was an increase in hydration measurements compared to baseline, in both immediate scores and cumulative long-term scores. At weeks 4 and 8, there was a statistically significant increase in hydration compared to baseline and the prior visit. Participants' assessments progressively increased over 2-, 4-, and 8-week intervals with significantly favorable ratings in all measured parameters. Similarly, investigator assessment grades were statistically significant (p < 0.0001) for decreased fine lines/wrinkling, crepiness, texture, erythema, and dryness, and increased (p < 0.0001) for moisture/hydration. Histology revealed increased CD44 staining in 6 of the 7 participants biopsied, denoting increased HA stimulation. In all of the participant biopsies, H&E staining demonstrated improvement in solar elastosis. Photography revealed remarkable improvement in erythema, tone, and texture. CONCLUSIONS: The study results demonstrated that the formulation produced significant improvements in immediate and long-term hydration effects on the skin as measured by the skin hydration sensor, 'wearifi' technology, comparison of before and after biopsies, and participant and investigator assessments. This high MW HA formulation produced excellent clinical improvement in skin health and hydration.
Assuntos
Ácido Hialurônico , Envelhecimento da Pele , Face , Humanos , Ácido Hialurônico/efeitos adversos , Peptídeos , Resultado do TratamentoRESUMO
BACKGROUND: The most severe complications following soft tissue filler injections result from the intraarterial administration of the filler product. Although hyaluronic acid-based filler can be trans-arterially dissolved with hyaluronidase, no information is available on calcium hydroxylapatite (CaHA)-based fillers. OBJECTIVE: The authors sought to test whether CaHA-based fillers can be trans-arterially dissolved by sodium thiosulfate (STS) when evaluated in cadaveric and in vitro models. METHODS: Human cadaveric facial arterial segments were each filled with 0.2 cc of commercially available CaHA product and submerged for 24 hours in 4 different STS-containing solutions: 10 cc STS (300 mg/cc) (pure, 1:1 dilution, 1:2 dilution), 0.9% saline and 10 cc STS (300 mg/cc), and 300 IU (bovine) hyaluronidase in a 1:1 ratio. RESULTS: Intraarterial CaHA was detected in human facial artery segments after 24 hours independent of the STS concentration employed. Submerging the arterial segments in STS (300 mg/cc) and 300 IU (bovine) hyaluronidase (1:1 ratio) also did not dissolve the intraarterial CaHA product. Gray scale analyses did show, however, that increasing concentrations of STS resulted in increased disintegration of CaHA in an in vitro experimental setting. CONCLUSIONS: The results of this study indicate that STS is limited in its potential to dissolve intraarterial CaHA of cadaveric human facial arteries, despite the fact that it appears effective when in direct contact with the CaHA. Adverse events caused by intraarterial administration of CaHA-based fillers still lack a suitable antidote.
Assuntos
Técnicas Cosméticas , Preenchedores Dérmicos , Animais , Materiais Biocompatíveis , Cadáver , Cálcio , Bovinos , Preenchedores Dérmicos/efeitos adversos , Durapatita , Humanos , TiossulfatosRESUMO
BACKGROUND: Topical melatonin is a potent antioxidant, yet there have been few clinical studies on its anti-aging effects on the skin. OBJECTIVES: To clinically assess the anti-aging efficacy and safety of a new 3-in-1 night facial serum (NFS) combining melatonin with bakuchiol, a novel retinol-like ingredient, and ascorbyl tetraisopalmitate, in all skin types. METHODS: Five clinical studies were performed, with a total of 103 subjects treated from 28 to 84 days. Under dermatologist supervision, a 3-month efficacy and safety study evaluated anti-aging properties by clinical scoring and instrumental evaluations. Two studies evaluated skin hydration properties for 12 hours after a single application of NFS. Two studies were performed in oily skin: a 1-month efficacy and safety study and a 1-month comedogenesis study. RESULTS: After 12 weeks, clinical evaluation showed a statistically significant decrease in wrinkles (11%), an increase in skin firmness (8%), a reduction in redness (70%; P < 0.01 for all), and an overall improvement in skin quality and complexion. The reduction in wrinkles and the increase in skin firmness were also supported by instrumental evaluations (Dermatop and Dynaskin). Hydration levels increased significantly from 30 minutes until 12 hours and transepidermal water loss significantly decreased after 4H and 6H. Subjects favorably evaluated the efficacy and cosmetic properties of the serum, and it was well tolerated in all skin types including oily skin. CONCLUSIONS: This 3-in-1 NFS showed significant clinical anti-aging effects when applied once daily and was well tolerated.
Assuntos
Cosméticos/administração & dosagem , Envelhecimento da Pele/efeitos dos fármacos , Higiene da Pele/métodos , Administração Cutânea , Adolescente , Adulto , Idoso , Ácido Ascórbico/administração & dosagem , Ácido Ascórbico/efeitos adversos , Cosméticos/efeitos adversos , Cosméticos/química , Face , Feminino , Voluntários Saudáveis , Humanos , Masculino , Melatonina/administração & dosagem , Melatonina/efeitos adversos , Pessoa de Meia-Idade , Palmitatos/administração & dosagem , Palmitatos/efeitos adversos , Fenóis/administração & dosagem , Fenóis/efeitos adversos , Estudos Prospectivos , Pele/efeitos dos fármacos , Pele/metabolismo , Resultado do Tratamento , Perda Insensível de Água/efeitos dos fármacos , Adulto JovemAssuntos
Agonistas alfa-Adrenérgicos/uso terapêutico , Eritema/tratamento farmacológico , Dermatoses Faciais/tratamento farmacológico , Oximetazolina/uso terapêutico , Creme para a Pele/uso terapêutico , Adolescente , Agonistas alfa-Adrenérgicos/administração & dosagem , Adulto , Eritema/etiologia , Dermatoses Faciais/etiologia , Humanos , Oximetazolina/administração & dosagem , Rosácea/complicações , Índice de Gravidade de Doença , Creme para a Pele/efeitos adversos , Fatores de Tempo , Adulto JovemRESUMO
BACKGROUND: Limited treatments are available for persistent erythema of rosacea. OBJECTIVE: To examine the long-term safety and efficacy of oxymetazoline cream 1.0% in patients with rosacea with moderate-to-severe persistent erythema. METHODS: Patients applied oxymetazoline once daily for 52 weeks. Safety assessments included treatment-emergent adverse events (TEAEs), skin blanching, inflammatory lesion counts, telangiectasia, disease severity, and rebound effect. Efficacy was assessed by the Clinician Erythema Assessment and Subject Self-Assessment composite score at 3 and 6 hours after the dose on day 1 and at weeks 4, 26, and 52. RESULTS: Among 440 patients, 8.2% reported treatment-related TEAEs; the most common were application-site dermatitis, paresthesia, pain, and pruritus. The rate of discontinuation due to adverse events (mostly application-site TEAEs) was 3.2%. No clinically meaningful changes were observed in skin blanching, inflammatory lesions, or telangiectasia. At week 52, 36.7%, and 43.4% of patients achieved a 2-grade or greater composite improvement from baseline in both Clinician Erythema Assessment and Subject Self-Assessment 3 and 6 hours after a dose, respectively. Less than 1% of patients experienced a rebound effect following treatment cessation. LIMITATIONS: A vehicle-control group was not included. CONCLUSION: This long-term study demonstrated sustained safety, tolerability, and efficacy of oxymetazoline for moderate-to-severe persistent erythema of rosacea.
Assuntos
Eritema/tratamento farmacológico , Dermatoses Faciais/tratamento farmacológico , Oximetazolina/uso terapêutico , Segurança do Paciente , Rosácea/tratamento farmacológico , Administração Cutânea , Adolescente , Adulto , Relação Dose-Resposta a Droga , Esquema de Medicação , Eritema/diagnóstico , Dermatoses Faciais/diagnóstico , Feminino , Humanos , Masculino , Pessoa de Meia-Idade , Medidas de Resultados Relatados pelo Paciente , Estudos Prospectivos , Rosácea/diagnóstico , Índice de Gravidade de Doença , Creme para a Pele/administração & dosagem , Fatores de Tempo , Resultado do Tratamento , Estados Unidos , Adulto JovemRESUMO
In a society where stigma surrounds cosmetic procedures and yet a thin and sculpted physique is idealized, noninvasive body contouring satisfies the demand to reduce excess and undesired body fat in areas that persist despite exercise and diet. Numerous devices are available to meet this need; however, choosing the "perfect" device is challenging because the science and data are often limited with variable results. In this paper, we review 7 US Food and Drug Administration-approved noninvasive body contouring therapies in hopes of providing some clarity to this area.
Assuntos
Contorno Corporal/métodos , Tecido Adiposo , Contorno Corporal/efeitos adversos , Contorno Corporal/instrumentação , Crioterapia/efeitos adversos , Crioterapia/instrumentação , Crioterapia/métodos , Ácido Desoxicólico/administração & dosagem , Ácido Desoxicólico/efeitos adversos , Fármacos Dermatológicos/administração & dosagem , Fármacos Dermatológicos/efeitos adversos , Tratamento por Ondas de Choque Extracorpóreas/efeitos adversos , Tratamento por Ondas de Choque Extracorpóreas/instrumentação , Tratamento por Ondas de Choque Extracorpóreas/métodos , Humanos , Lasers Semicondutores/efeitos adversos , Lasers Semicondutores/uso terapêutico , Terapia por Radiofrequência/instrumentação , Terapia por Radiofrequência/métodosRESUMO
Cellulite is a condition that affects the majority of postpubertal women and can negatively impact quality of life. This review discusses several proposed pathophysiologies of cellulite, and examines treatment options that have been utilized, focusing on the etiologic factor targeted by the therapies. This approach aims to help clarify the pathogenesis of cellulite and provide a road map for developing effective treatment paradigms for patients.
Assuntos
Celulite/fisiopatologia , Celulite/terapia , Técnicas Cosméticas , Celulite/etiologia , Celulite/patologia , Colágeno/fisiologia , Edema/patologia , Feminino , Humanos , Masculino , Microcirculação , Desnaturação Proteica , Qualidade de Vida , Pele/fisiopatologia , Gordura Subcutânea/patologiaRESUMO
INTRODUCTION: A topical proprietary procedural enhancement system (PES) containing a combination of active ingredients including a tripeptide and hexapeptide (TriHex Technology™, Alastin Procedure Enhancement Invasive System, ALASTIN Skincare™, Inc., Carlsbad, CA) has been used successfully to aid in healing and improve symptomatology following resurfacing procedures.
METHODS: PES (Gentle Cleanser, Regenerating Skin Nectar with TriHex Technology™, Ultra Nourishing Moisturizer with TriHex Technology™, Soothe + Protect Recovery Balm, Broad Spectrum 30+ Sunscreen) was compared to a basic regimen (Aquaphor™, Cerave™ cleanser, Vanicream™, Alastin Broad Spectrum 30+ Sunscreen) in a split face/ décolleté trial following fractional non-ablative thulium-doped resurfacing treatment to the face or décolleté. The skin was pre-conditioned and treated during and after the procedure using the two regimens.
RESULTS: A blinded investigator rated the PES statistically superior to the basic regimen on healing post-laser treatment on day 4 based on lentigines, texture, and Global Skin Quality. Subjects also reported 'better looking and feeling' skin on the PES side.
CONCLUSION: PES appears to improve healing post-non ablative thulium-doped resurfacing treatment to the face/décolleté in comparison with standard of care.
J Drugs Dermatol. 2017;16(7):707-710.
.Assuntos
Lasers de Gás/uso terapêutico , Envelhecimento da Pele/efeitos dos fármacos , Envelhecimento da Pele/patologia , Creme para a Pele/administração & dosagem , Protetores Solares/administração & dosagem , Procedimentos Cirúrgicos Dermatológicos/métodos , Face/patologia , Feminino , Humanos , Regeneração da Pele por Plasma/métodos , Método Simples-Cego , Tórax/efeitos dos fármacos , Tórax/patologia , Resultado do TratamentoRESUMO
We present two cases of neonates born with symmetric aplasia cutis congenita associated with intrauterine fetal demise of cotwins during the early second trimester. Fetus papyraceus resulting in aplasia cutis congenita is a rare association with many clinical presentations, including extratruncal symmetric lesions and small linear, arcuate, and triangular lesions when twin intrauterine demise occurs after the first trimester.